Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS)

被引:0
|
作者
A. Cantù Rajnoldi
S. Fenu
G. Kerndrup
E. R. van Wering
C. M. Niemeyer
I. Baumann
机构
[1] Istituti Clinici di Perfezionamento,Dip.to di Medicina di Laboratorio
[2] Azienda Ospedaliera San Giovanni-Addolorata UOD Ematologica,Institute of Pathology
[3] Odense University Hospital,Division of Hematology and Oncology, Department of Pediatrics and Adolescent Medicine
[4] Dutch Childhood Leukemia Study Group,Institute of Pathology
[5] University Hospital Freiburg,undefined
[6] University Erlangen-Nuremberg,undefined
来源
Annals of Hematology | 2005年 / 84卷
关键词
Myelodysplastic syndrome; Morphological features of dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
In the absence of genetic abnormalities, the diagnoses of myelodysplastic syndromes (MDS) is primarily based on the presence of dysplasia in blood and marrow cells. Currently, there is no standardized approach to evaluate dysplasia. International cooperative study groups like the European Working Group on MDS in Childhood (EWOG-MDS) depend, however, on a concordance in diagnoses by their national reference centres for morphology. In EWOG-MDS, the morphological diagnoses of all cases enrolled from Scandinavia, the Netherlands, Germany, the Czech Republic, Austria and Italy are established by five experienced pathologists or hematologists cooperating in a morphology board. To study their concordance in evaluating myelodysplastic disorders, members of the morphology board initiated blinded reviews of smears of blood and bone marrow aspirates of known cases. Four features of dysplasia in granulopoiesis, erythropoiesis and megakaryopoiesis were assessed on May–Grünwald–Giemsa stained smears. In a final review of six blinded cases, good concordance for these features was achieved among the five observers. Accurately defined and restrictively applied cellular features of dysplasia are an important tool to improve and ensure the concordance in the diagnosis of MDS among investigators. For cooperative groups, agreement on the evaluation of the morphological assessment of dysplasia is a prerequisite.
引用
收藏
页码:429 / 433
页数:4
相关论文
共 50 条
  • [21] Unrelated cord blood transplantation for juvenile myelomonocytic leukaemia and other myelodysplastic syndromes in children, a survey on behalf of EWOG-MDS and Eurocord
    Madureira, A.
    Teira, P.
    Rocha, V.
    Picardi, A.
    Champagne, M.
    O'Brien, T.
    Vora, A.
    Stein, J.
    Woolfrey, A.
    Olive, T.
    Stary, J.
    Bertrand, Y.
    Garnier, F.
    Niemeyer, C.
    Gluckman, E.
    Locatelli, F.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S10 - S10
  • [22] Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
    Goetze, Katharina
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Haase, Detlef
    Luebbert, Michael
    Aul, Carlo
    Ganser, Arnold
    Germing, Ulrich
    Hofmann, Wolf-Karsten
    ANNALS OF HEMATOLOGY, 2010, 89 (09) : 841 - 850
  • [23] Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
    Katharina Götze
    Uwe Platzbecker
    Aristoteles Giagounidis
    Detlef Haase
    Michael Lübbert
    Carlo Aul
    Arnold Ganser
    Ulrich Germing
    Wolf-Karsten Hofmann
    Annals of Hematology, 2010, 89 : 841 - 850
  • [24] Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)
    Nomdedeu, Meritxell
    Galvo, Xavier
    Costa, Dolors
    Arnan, Montserrat
    Pomares, Helena
    Sanz, Guillermo
    Valcarcel, David
    Luno, Elisa
    Ramos, Fernando
    Diaz-Campelo, Maria
    Collado, Rosa
    de Paz, Raquel
    Falantes, Jose-Francisco
    Pedro, Carme
    Esteve, Jordi
    Andreu, Rafael
    Ardanaz, Maria-Teresa
    Sanchez-Garcia, Joaquin
    Tormo, Mar
    Gedena, Maria-Teresa
    Arrizabalaga, Beatriz
    Gonzalez, Bernardo
    Marco, Victor
    Brunet, Salut
    Pereira, Arturo
    BLOOD, 2015, 126 (23)
  • [25] Stem cell transplantation (SCT) for children with juvenile myelomonocytic leukemia (JMML) and myelodysplastic syndrome (MDS) treated on the EWOG-MDS protocol:: A single-center experience
    Strahm, B
    Duffner, U
    Peters, A
    Wider, S
    Büchner, J
    Lenartz, E
    Fischer, A
    Nöllke, P
    Kontny, U
    Niemeyer, CM
    BONE MARROW TRANSPLANTATION, 2002, 29 : S4 - S4
  • [26] Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
    Komrokji, Rami S.
    DeZern, Amy E.
    Zell, Katrina
    Al Ali, Najla H.
    Estling, Christopher
    Zimmerman, Cassie
    Hand, Wesley
    Brown, Francis
    Rizzo, Nicole
    Barnard, John
    Roboz, Gail J.
    Garcia-Manero, Guillermo
    Steensma, David P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [27] Allogenic stem cell transplantation for children with advanced MDS:: results from the EWOG-MDS study group employing a pre-transplant preparative regimen with busulfan, cyclophosphamide and melphalan
    Niemeyer, CM
    Zecca, M
    Korthoff, E
    Duffner, U
    Zintl, F
    Ebell, W
    Stary, J
    Dillo, D
    Bader, P
    Peters, C
    Schmugge, M
    Sedlacek, P
    van Heuvel, M
    Bergsträsser, E
    Trebo, M
    Nölke, P
    Locateffl, F
    BONE MARROW TRANSPLANTATION, 2005, 35 : S20 - S20
  • [28] Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group
    Symeonidis, A.
    Galanopoulos, A.
    Hatzimichael, E.
    Kouraklis, A.
    Korantzis, I.
    Kartasis, Z.
    Giannakoulas, N.
    Michali, E.
    Kokkini, G.
    Vagia, M.
    Kotsopoulou, M.
    Pappa, V.
    Papadaki, E.
    Bourantas, K.
    Matsouka, P.
    Anagnostopoulos, N.
    Zoumbos, N.
    LEUKEMIA RESEARCH, 2009, 33 : S125 - S125
  • [29] Allogeneic stem cell transplantation for children with advanced primary MDS: Results from the EWOG-MDS study group employing a pre-transplant preparative regimen with busulfan, cyclophosphamide and melphalan.
    Niemeyer, CM
    Zecca, M
    Korthoff, E
    Duffner, U
    Zintl, F
    Ebell, W
    Stary, J
    Dilloo, D
    Peters, C
    Schmugge, M
    Sedlacek, P
    Messina, C
    van Heuvel, M
    Bergstraesser, E
    Trebo, M
    Noellke, P
    Locatelli, F
    BLOOD, 2004, 104 (11) : 632A - 632A
  • [30] Evaluation of 396 successfully analyzed bone marrow karyotypes of children with MDS and juvenile myelomonocytic leukemia (JMML) as collected by the European working group of childhood MDS.
    Harbott, J
    Biondi, A
    Haas, OA
    Kerndrup, GB
    Michalova, K
    Sainati, L
    Slater, R
    Fenu, S
    Hasle, H
    Kühne, T
    Mann, G
    Stary, J
    van Wering, E
    Baumann, I
    Nöllke, P
    Rogge, T
    Zimmermann, M
    Niemeyer, CM
    BLOOD, 1999, 94 (10) : 661A - 661A